Aratana Therapeutics Inc (NASDAQ:PETX) Institutional Investor Sentiment Is 1.41

June 15, 2018 - By Vivian Currie

Aratana Therapeutics, Inc. (NASDAQ:PETX) Logo

Sentiment for Aratana Therapeutics Inc (NASDAQ:PETX)

Aratana Therapeutics Inc (NASDAQ:PETX) institutional sentiment decreased to 1.41 in 2018 Q1. Its down -0.15, from 1.56 in 2017Q4. The ratio turned negative, as 45 hedge funds increased and started new positions, while 32 sold and trimmed holdings in Aratana Therapeutics Inc. The hedge funds in our partner’s database now possess: 31.01 million shares, up from 30.34 million shares in 2017Q4. Also, the number of hedge funds holding Aratana Therapeutics Inc in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 12 Reduced: 20 Increased: 35 New Position: 10.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. The company has market cap of $233.45 million. The Company’s product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. It currently has negative earnings. The firm markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs.

The stock decreased 2.17% or $0.11 during the last trading session, reaching $4.95. About 323,701 shares traded. Aratana Therapeutics, Inc. (NASDAQ:PETX) has declined 9.29% since June 15, 2017 and is downtrending. It has underperformed by 21.86% the S&P500.

Analysts await Aratana Therapeutics, Inc. (NASDAQ:PETX) to report earnings on August, 2. They expect $-0.19 earnings per share, up 26.92 % or $0.07 from last year’s $-0.26 per share. After $-0.19 actual earnings per share reported by Aratana Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Broadfin Capital Llc holds 2.95% of its portfolio in Aratana Therapeutics, Inc. for 4.29 million shares. Engaged Capital Llc owns 2.00 million shares or 1.2% of their US portfolio. Moreover, General American Investors Co Inc has 0.68% invested in the company for 1.62 million shares. The New York-based Awm Investment Company Inc. has invested 0.52% in the stock. Mpm Asset Management Llc, a Massachusetts-based fund reported 250,000 shares.

Since January 1, 0001, it had 0 buys, and 3 selling transactions for $307,923 activity.

Aratana Therapeutics, Inc. (NASDAQ:PETX) Ratings Coverage

Ratings analysis reveals 100% of Aratana’s analysts are positive. Out of 4 Wall Street analysts rating Aratana, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $6.0 while the high is $10.0. The stock’s average target of $7.88 is 59.19% above today’s ($4.95) share price. PETX was included in 8 notes of analysts from December 18, 2017. The rating was maintained by H.C. Wainwright with “Buy” on Monday, March 19. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) has “Buy” rating given on Monday, May 7 by H.C. Wainwright. C.L. King upgraded it to “Buy” rating and $7.5 target in Monday, March 12 report. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, March 27. H.C. Wainwright maintained Aratana Therapeutics, Inc. (NASDAQ:PETX) on Tuesday, January 16 with “Buy” rating. As per Wednesday, December 27, the company rating was initiated by C.L. King. Credit Suisse maintained it with “Outperform” rating and $8 target in Friday, March 16 report. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) has “Hold” rating given on Monday, December 18 by Stifel Nicolaus.

More news for Aratana Therapeutics, Inc. (NASDAQ:PETX) were recently published by: Streetinsider.com, which released: “Aratana Therapeutics (PETX) Appoints Craig Barbarosh and Lowell Robinson to Board in Cooperation Agreement with …” on May 21, 2018. Streetinsider.com‘s article titled: “Aratana Therapeutics (PETX) Files Supplemental NADA for FDA Approval of NOCITA (bupivacaine liposome injectable …” and published on June 01, 2018 is yet another important article.

Aratana Therapeutics, Inc. (NASDAQ:PETX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: